Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.53 |
| ▸ | FAAH | O00519 | 7/20 | 0.47 |
| ▸ | CES1 | P23141 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivalate SCHEMBL3414635 | 0.88 | SMPD1 (0.47) | CES2MEN1KMT2AHSD17B10SMPD1 | |
| Bicarbonate SCHEMBL27083092 | 0.88 | SMPD1 (0.50) | CES2MEN1KMT2AHSD17B10SMPD1 | |
| Trifluoroacetic Acid SCHEMBL28160743 | 0.86 | CES2 (0.55) | CES2FAAHCES1MEN1CYP1A2 | |
| Acetic Acid SCHEMBL3139399 | 0.86 | SMPD1 (0.48) | CES2MEN1KMT2AHSD17B10SMPD1 | |
| Acetic Acid SCHEMBL9224621 | 0.86 | SMPD1 (0.48) | CES2MEN1KMT2AHSD17B10SMPD1 | |
| Acetic Acid SCHEMBL4367052 | 0.86 | SMPD1 (0.48) | CES2MEN1KMT2AHSD17B10SMPD1 | |
| Acetic Acid SCHEMBL11691620 | 0.86 | SMPD1 (0.48) | CES2MEN1KMT2AHSD17B10SMPD1 | |
| Bicarbonate SCHEMBL1689393 | 0.86 | FDPS (0.48) | CES2MEN1KMT2AHSD17B10SMPD1 | |
| Trifluoroacetic Acid SCHEMBL27124069 | 0.84 | MEN1 (0.38) | CES2FAAHCES1MEN1CYP1A2 | |
| Acetic Acid SCHEMBL3140123 | 0.84 | FDPS (0.47) | CES2MEN1KMT2AHSD17B10SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7247434-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7052846-B2 | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques | OPERON BIOTECHNOLOGIES, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060057566-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | QIAGEN GENOMICS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| US-20040115694-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | QIAGEN GENOMICS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6623928-B2 | Determining the sequence of a nucleic acid; obtain sample, incubate with labeled probe, separate labeled nucleotide sequences, remove label, detect labels | QIAGEN GENOMICS, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6613508-B1 | Spectrometry; electrophoresis; chromatography; separation; cleavage; labels; probes; primers; hybridization; use of tags in a wide variety of nucleic acid reactions where separation of nucleic acid molecules based on size is required | QIAGEN GENOMICS, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-0990047-B1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | QIAGEN GENOMICS INC (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020119456-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | AGILENT TECHNOLOGIES, INC. | 2002-08-29 | — | — | US | disclosed |
| US-6312893-B1 | GENERATING TAGGED NUCLEIC ACID FRAGMENTS WHICH ARE COMPLEMENTARY TO SELECTED TARGET NUCLEIC ACID MOLECULE; SEPARATION OF TAGGED FRAGMENTS; CLEAVING THE TAGS; DETECTING TAGS BY NON-FLUORESCENT SPECTROMETRY OR POTENTIOMETRY | QIAGEN GENOMICS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0990047-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | Rapigene, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | CES2 2530/4885FAAH 2651/4885CES1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.